Jeito Capital Closes Its Latest Fund, Jeito I, at $630m

Sep 20, 2021 | News

Jeito Capital, a rapidly growing, new, independent Private Equity firm dedicated to biotech and biopharma, today announced the final closing of its first fund, Jeito I, at $630m, exceeding its original target of €500m. Jeito I is the largest European fund dedicated to supporting companies in the life sciences sector.

Jeito Capital is building a strong and diversified portfolio of biotech and biopharma companies primarily based in Europe with global reach, focused on the treatment of life-threatening diseases. Jeito’s unique investment model provides support to entrepreneurs by a multi-talented team of experts integrated in the investment team across the entire drug development value chain, from translational science to market access and commercialization, providing significant capital in continuity, up to $100m in a single company.

Jeito I investments to date include French-based SparingVision and InnoSkel, in the fields of genomic ophthalmology and rare skeletal disorders, respectively, Dutch biotech Neogene Therapeutics in solid tumors, UK-based Pulmocide in severe respiratory diseases, and Swiss-French Alentis Therapeutics in fibrosis and related cancers.

Free Webinar: The Primary Step in Creating Value: How the Right Corporate Governance Can Drive Growth

Learn More
  • To what extend can the relationship between the GP and board impact the company?
  • How can GPs ensure trickle down change in organisations?
  • How can technology help bridge the gap between GPs and management boards?

Jeito I attracted leading global investors including the European Investment Fund (EIF), the American pension fund Teacher Retirement System of Texas (TRS), which has made its first-ever investment into a European fund dedicated to the biotech sector, and Temasek, a global investor headquartered in Singapore with deep experience investing in life sciences.

Founded and directed by Dr Rafaèle Tordjman, MD PhD, Jeito Capital was launched in January 2020 and completed a first funding round of €200m with the strategic support of investors such as Aviva, AXA, the French public investment bank (BPI), BNP Paribas Fortis, the Caisse des Dépôts et des Consignations (CDC), CNP Assurances, Pro BTP, etc. In the following months Sanofi selected Jeito as its first ever investment into a private French-based fund, investing €50m.

Rafaèle Tordjman, Founder and CEO of Jeito Capital, said: “We are extremely proud to have closed Jeito I, making it the largest European fund dedicated to the life sciences sector. We have thus exceeded our original target and have attracted a group of leading and diverse global investors, a testament to Jeito’s unique investment model and team. I am pleased to welcome new investors including the EIF, TRS and Temasek and would like to thank our existing investors for their unwavering support. This important achievement will enable Jeito to fulfill its mission: to provide continuous financial support and industry expertise to talented entrepreneurs to accelerate the development of revolutionary therapies and guaranteeing patients quicker access to medical innovations.”

Sabine Dandiguian, Managing Partner of Jeito Capital, added: “This exceptional fundraising success confirms Jeito’s investment model driven by Rafaèle Tordjman. I am very proud to have been part of this multi-talented team since the very beginning which, thanks to its expertise across all stages of company development, is able to uncover and support the best scientific quality start-ups in Europe, with a global reach. Thanks to Jeito’s dynamic and collaborative team we have already developed a pipeline of high-quality deal flow. We look forward to achieving our shared ambitions and making a significant and meaningful difference to patients’ lives.”

Source: Yahoo Finance

Can’t stop reading? Read more